Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Simon

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
The New England Journal of Medicine|May 10, 2023
First-Line Venetoclax Combinations in Chronic Lymphocytic LeukemiaBarbara Eichhorst, Carsten U Niemann, Arnon P Kater, et al.
Blood|May 12, 2023
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinationsMoritz Fürstenau, Yvonne J Thus, Sandra Robrecht, et al.
The New England Journal of Medicine|December 8, 2025
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic LeukemiaOthman Al-Sawaf, Janina Stumpf, Can Zhang, et al.
Blood|March 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trialMoritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
The New England Journal of Medicine|May 10, 2023
First-Line Venetoclax Combinations in Chronic Lymphocytic LeukemiaBarbara Eichhorst, Carsten U Niemann, Arnon P Kater, et al.
Blood|May 12, 2023
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinationsMoritz Fürstenau, Yvonne J Thus, Sandra Robrecht, et al.
The New England Journal of Medicine|December 8, 2025
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic LeukemiaOthman Al-Sawaf, Janina Stumpf, Can Zhang, et al.
Blood|March 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trialMoritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht, et al.
Pageof 11